Search research articles
Contact Us
Filters
Showing results (111-120 of 233) with videos related to
Page
of 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2014
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study
Markus M Heiss, Michael A Ströhlein, Carsten Bokemeyer, et al.
Cancer Chemotherapy and Pharmacology
|
March 15, 2011
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
Uwe Pelzer, Dirk Arnold, Peter Reitzig, et al.
Journal of Cancer Research and Clinical Oncology
|
January 31, 2025
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Gazanfer Belge, Markus Klemke, Bendix Hansen, et al.
Clinical Colorectal Cancer
|
October 14, 2021
Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Marianne Grønlie Guren, David Sebag-Montefiore, Pierfrancesco Franco, et al.
Onkologie
|
June 24, 2009
[Palliative treatment for colorectal cancer]
Susanna Hegewisch-Becker, Udo Vanhoefer, Stefan Kubicka, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 16, 2010
Kinematic and electromyographic tools for characterizing movement disorders in mice
Hans C Scholle, H A Jinnah, Dirk Arnold, et al.
Expert Review of Anticancer Therapy
|
August 19, 2017
Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
Eva Segelov, Florian Lordick, David Goldstein, et al.
Frontiers in Oncology
|
November 24, 2018
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial
Sebastian Stintzing, Boryana Ivanova, Ingrid Ricard, et al.
BMC Cancer
|
October 5, 2013
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
Alexander Stein, Albrecht Kretzschmar, Dirk Behringer, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, et al.
Page
of 24
Search research articles
Search
Showing results (111-120 of 233) with videos related to
Sort By:
Page
of 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2014
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study
Markus M Heiss, Michael A Ströhlein, Carsten Bokemeyer, et al.
Cancer Chemotherapy and Pharmacology
|
March 15, 2011
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group
Uwe Pelzer, Dirk Arnold, Peter Reitzig, et al.
Journal of Cancer Research and Clinical Oncology
|
January 31, 2025
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Gazanfer Belge, Markus Klemke, Bendix Hansen, et al.
Clinical Colorectal Cancer
|
October 14, 2021
Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Marianne Grønlie Guren, David Sebag-Montefiore, Pierfrancesco Franco, et al.
Onkologie
|
June 24, 2009
[Palliative treatment for colorectal cancer]
Susanna Hegewisch-Becker, Udo Vanhoefer, Stefan Kubicka, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 16, 2010
Kinematic and electromyographic tools for characterizing movement disorders in mice
Hans C Scholle, H A Jinnah, Dirk Arnold, et al.
Expert Review of Anticancer Therapy
|
August 19, 2017
Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
Eva Segelov, Florian Lordick, David Goldstein, et al.
Frontiers in Oncology
|
November 24, 2018
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial
Sebastian Stintzing, Boryana Ivanova, Ingrid Ricard, et al.
BMC Cancer
|
October 5, 2013
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
Alexander Stein, Albrecht Kretzschmar, Dirk Behringer, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, et al.
Page
of 24